Suria Hamza 4
4 · ANAPTYSBIO, INC · Filed Nov 5, 2021
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
Suria Hamza
DirectorPresident, CEO
Transactions
- Exercise/Conversion
Common Stock
2021-11-04$1.12/sh+6,059$6,786→ 73,695 total - Sale
Common Stock
2021-11-04$35.00/sh−6,059$212,065→ 67,636 total - Sale
Common Stock
2021-11-05$35.00/sh−14,302$500,570→ 67,636 total - Exercise/Conversion
Common Stock
2021-11-05$1.12/sh+14,302$16,018→ 81,938 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-11-04−6,059→ 14,302 totalExercise: $1.12Exp: 2021-12-08→ Common Stock (6,059 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-11-05−14,302→ 0 totalExercise: $1.12Exp: 2021-12-08→ Common Stock (14,302 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The stock option grant was issued on December 9, 2011, is fully vested and exercisable until its expiration date of December 8, 2021.
- [F3]In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.